BRCA1 and breast cancer: Phase 2 ABRAZO trial with 84 BRCA1/2-mutated metastatic breast cancer patients receiving talazoparib monotherapy resulted in a 37% response rate for patients who previously received more than two advanced breast cancer cytotoxic regimens without exposure to platinum chemotherapy and 21% response rate for patients who previously are responsive to platinum chemotherapy (median PFS 5.6 vs. 4.0 months, respectively) [103].